Proactive Investors - Run By Investors For Investors

Small Cap Wrap: Altitude Group, Avingtrans, Blue Prism, Conroy Gold and Natural Resources, Lok’n Store..

Small Cap Wrap: Altitude Group, Avingtrans, Blue Prism, Conroy Gold and Natural Resources, Lok’n Store..

Altitude Group  (LON:ALT 16.75p/£7.45m)
Altitude Group, the provider of innovative technology solutions for small to medium sized businesses, announced that its wholly owned subsidiary, Customer Focus Software Inc., has agreed a five-year agreement with Philadelphia, PA based AI Mastermind. A1 Mastermind is a leading buying group serving more than 1,000 promotional product resellers representing over $200m in annual sales in North America. Under the terms of the agreement, Altitude will provide each AI Mastermind member with an ecommerce website that uses the Group's unique proprietary technology. Altitude will receive a share of the gross margin on all orders that are processed through the platform. The agreement is for an initial five-year term, with automatic renewal for a further five years. The Directors expect the first customers to be live by October 2016 and the deal to be earnings enhancing from launch.
 
Avingtrans (LON:AVG 193.88p/£53.86m)
Avingtrans, a manufacturer of critical components and associated services to the global energy and medical sectors, announced that Maloney Metalcraft, part of Avingtrans PLC's Energy & Medical division, has secured a contract with EDF Energy, worth £3.5m, to supply components for their current fleet of seven nuclear power stations across the UK. Maloney Metalcraft will supply gas-cooling process-critical valves for each of the seven EDF managed Advanced Gas-Cooled Reactors around the country (Dungeness B, Hinkley Point B, Hunterson B, Hartlepool, Heysham 1, Heysham 2 and Torness). The contract is part of a life extension programme that will also see Maloney Metalcraft providing engineering support and on-site services to EDF Energy as part of the deal. These contracts will continue until the end of life of the stations.
 
Blue Prism (LON:PRSM 211.10p/£131.33m)
Blue Prism, a leader in Robotic Process Automation (RPA), provided an update on current trading. Blue Prism has continued to enjoy strong pipeline progress. The Group has won a number of new contracts including a contract to deploy its RPA solution to a global tier-1 bank through one of its major alliance partners. This is a significant contract win for Blue Prism that provides a strong validation of its partner-led sales model and whilst the size of the contract today is uncertain, the Board believes it has the potential to become the largest deployment of Blue Prism's software robots to date. Alongside these contract wins, the Group has recently secured a contract renewal with one of its largest customers, a UK-headquartered global tier-1 bank, which signed a new three year commitment. Together, the renewals and the continued momentum in new business wins in the year to date, mean that, subsequent to the outlook detailed in the Group's interim results, we are confident that Blue Prism will outperform the Board's current expectations for the full year.
 
Conroy Gold and Natural Resources (LON:CGNR 30.65p/£3.47m)*
Conroy Gold and Natural Resources, the gold exploration and development company focused on Ireland and Finland, announced that an independent study by structural consultant Dr. Francis Murphy has confirmed the continuity of the gold lodes at the Company’s Clontibret gold target. The structural study was carried out on the stream bedrock in Clontibret. Eight gold lodes were identified in the stream bedrock. These lodes all corresponded to gold lodes previously identified by the drilling programme. The confirmation of continuity in the gold lodes, taken in conjunction with drilling results and channel sampling results from the old antimony mine workings at Clontibret enhances the Company’s understanding of gold mineralisation within the Clontibret gold deposit. This demonstration of the continuity of the gold mineralisation at Clontibret is a further essential step forward as the Company proceeds with its Clay Lake-Clontibret gold mining project.
 
Lok’n Store (LON:LOK 322.00p/£86.72m)
Lok'nStore, the fast growing self-storage Company, announce the signing of management contracts to develop and operate two new landmark stores. The two sites are in prominent retail locations in Hemel Hempstead, Hertfordshire and Broadstairs, Kent. Lok'nStore has secured planning permission for a purpose built landmark site in Hemel Hempstead which has been purchased by an international fund management group. The Broadstairs site is an existing building in a prominent location on a retail park that will be converted for storage use. Building work will commence immediately on both locations, funded by the owners of the properties, with opening scheduled for 2017. When developed these Managed Stores will add around 70,000 sq. ft. to the trading portfolio, an increase of 5 percent to the total managed or owned currently by the Company. With the addition of the new landmark sites recently acquired as Lok'nStore Owned Stores in Wellingborough and Gillingham, the Company will be operating thirty storage centres when these sites are completed. Lok'nStore will generate a return on these stores by charging management fees for the acquisition, branding and operation of the stores based on revenue and profits. These projects continue Lok'nStore's strategy of expanding the operating footprint of the business by developing both Managed Stores and Owned Stores while maintaining its strong balance sheet.

Oakley Capital (LON:OCL 127.94p/£243.80m)
Oakley Capital Investments, the company established to provide investors with access to the investment strategy being pursued by Oakley Capital Private Equity L.P. (Fund I) and its successor fund, Oakley Capital Private Equity II (Fund II), announced a trading update for the six months ended 30 June 2016. The Company, through its investment in Fund I, has an indirect interest in each of Fund I's portfolio companies representing 65.5 percent of Fund I's total commitments; and through its investment in Fund II, an indirect interest in each of Fund II's portfolio companies representing 38.1 percent of Fund II's total commitments. The Company's NAV will be in the range £2.12 - £2.15 per share representing an uplift of 12 - 15p per share versus the NAV of £2.00 per share as at 31 December 2015. Of the uplift in NAV per share, approximately 13p is attributable to the significant weakening of Sterling between 31 December 2015 and 30 June 2016.  The underlying performance of the portfolio in the Funds has been good, contributing to an uplift of up to 9p per share. There has been a fall in NAV per share of 7p due to the post-IPO share price of Time Out on 30 June 2016. The Company's NAV comprises cash, the investments in the Funds, short-term bridging finance for the Funds and loans provided to a number of the portfolio companies.
 
OptiBiotix Health (LON:OPTI 72.20p/£56.33m)*
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods. On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss.  The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss.  GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
 
Premier Veterinary Group (LON:PVG 147.00p/£21.24m)
Premier Veterinary Group announced that, through its wholly-owned subsidiary, Premier Vet Alliance Limited, it has signed a cooperation agreement for its preventative healthcare program for pets, Premier Pet Care Plan (PPCP), with Zoetis, one of the world's largest animal healthcare companies.  PPCP is branded as "Huisdieren Zorg Plan" (HZP) in the Netherlands. Since the introduction of HZP to the Dutch companion animal market in March 2015, the business has entered into contracts with over 10% of the available clinic market.  The cooperation agreement signed with Zoetis, an influential global manufacturer serving this market, will result in their representatives identifying and supporting practices which are interested in launching HZP in the Netherlands.  Working in close collaboration with Zoetis, this is expected to generate an acceleration of the penetration of HZP into the wider Dutch market. The available market for preventative healthcare programs for pets across the Netherlands is estimated at 1,100 veterinary practices, and an estimated 1.5 million dogs and 2.6 million.

ProMetic Life Sciences (TSX:PLI CAD3.04/CAD1,801.4m)*
ProMetic Life Sciences, announced that it has completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the Food and Drug Administration (FDA). The FDA has agreed to an accelerated regulatory approval pathway, given the rarity of the condition and the related unmet medical need. To secure an accelerated pathway approval, a drug must treat a serious condition, provide a meaningful advantage over available therapies and demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. ProMetic's Plasminogen has received an Orphan Drug Designation by the FDA and the European Commission for the US and the European markets respectively. ProMetic also received a Fast Track Designation by the FDA, a process designed to facilitate the development and expedite review of drugs and biologics intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
 
Sareum (LON:SAR 0.673p/£17.75m)*
Sareum, the specialist cancer drug discovery and development business, announced that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme. These patents describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer. The granting of these patents means that Sareum will have approved patent protection in China and Hong Kong for its Aurora+FLT3 inhibitor programme. The Company announced that similar patents were to be granted in the USA and Europe in September 2015. Other major territories, including Japan, are expected to follow in due course. Sareum's Aurora+FLT3 inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas. In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98% tumour inhibition. Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center (HMUBEC) in China.
 
Venn Life Sciences (LON:VENN 28.00p/£16.77m)
Venn Life Sciences, a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announced that it has signed a new contract worth €2.8m with a European Biotechnology client. The clinical trial is a Phase II study in the area of Immunotherapeutic treatments for Multiple Sclerosis and involves patients in six countries across Europe and commences in October 2016. Furthermore, Venn's Interactive Response Technology (IRT) department, which centralises the randomisation of patients for Phase I to IV clinical trials and manages the logistics of these studies, has successfully qualified as a service provider to a top ten Pharmaceutical client and has been awarded an initial project involving thirty sites in China. This vendor qualification is a significant milestone for the IRT division and represents an exciting opportunity to grow a global account.
 

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

 

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use